3 Companies Rising on Good News for Thursday 2nd March 2023
Episode 1228, Mar 02, 2023, 12:06 PM
3 Companies Rising on Good News for Thursday 2nd March 2023
1. Poolbeg Pharma #POLB - Positive Results POLB001 LPS Human Challenge Trial
Poolbeg Pharma a leading infectious disease focused biopharmaceutical company, announces the data readout from the bacterial lipopolysaccharide ('LPS') human challenge trial for POLB 001.
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Key Highlights
· POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines
· Treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo
· Trial results demonstrate expected utility in severe influenza and other acute inflammatory conditions
2. Verici Dx #VRCI - CLIA Certificate of Compliance
Verici Dx a developer of advanced clinical diagnostics for organ transplant has announced that it's achieved CLIA Certificate of Compliance for full commercial launch of Tutivia™
Successful CMS review and inspection solidify commercial positioning and represents a major milestone toward US Medicare reimbursement.
3. Capita #CPI - Full Year Results 2022
Revenue increased 2.4% to £2.8bn.
Order book of £5.8bn; strong weighted pipeline (£2.2bn) with 50% of pipeline from growth with existing and new clients.
Reported profit before tax of £61m (2021: £286m) as a result of reduced profits associated with disposals and current year non-cash goodwill impairment.
£397m reduction in net financial debt and leases (IFRS 16) to £482m (2021: £880m) funded by operating cash flow and disposals.
1. Poolbeg Pharma #POLB - Positive Results POLB001 LPS Human Challenge Trial
Poolbeg Pharma a leading infectious disease focused biopharmaceutical company, announces the data readout from the bacterial lipopolysaccharide ('LPS') human challenge trial for POLB 001.
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Key Highlights
· POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines
· Treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo
· Trial results demonstrate expected utility in severe influenza and other acute inflammatory conditions
2. Verici Dx #VRCI - CLIA Certificate of Compliance
Verici Dx a developer of advanced clinical diagnostics for organ transplant has announced that it's achieved CLIA Certificate of Compliance for full commercial launch of Tutivia™
Successful CMS review and inspection solidify commercial positioning and represents a major milestone toward US Medicare reimbursement.
3. Capita #CPI - Full Year Results 2022
Revenue increased 2.4% to £2.8bn.
Order book of £5.8bn; strong weighted pipeline (£2.2bn) with 50% of pipeline from growth with existing and new clients.
Reported profit before tax of £61m (2021: £286m) as a result of reduced profits associated with disposals and current year non-cash goodwill impairment.
£397m reduction in net financial debt and leases (IFRS 16) to £482m (2021: £880m) funded by operating cash flow and disposals.